A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 833-845

  Quartino, Angelica Linnea ^a   Friberg, Lena E ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Docetaxel; Myelosuppression; Neutropenia; NONMEM; Pharmacometrics; Population pharmacokinetic pharmacodynamic modeling

Indexed keywords

DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER PATIENT; CELL MATURATION; CELL TYPE; CONTROLLED CLINICAL TRIAL (TOPIC); FEEDBACK SYSTEM; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MONOTHERAPY; NEUTROPHIL COUNT; NONBIOLOGICAL MODEL; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOLID TUMOR; VISCERAL METASTASIS; BIOLOGICAL MODEL; DRUG ADMINISTRATION; DRUG EFFECT; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; NEOPLASM; NEUTROPHIL; NONLINEAR SYSTEM; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE MARROW; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; LEUKOCYTES; MODELS, IMMUNOLOGICAL; MODELS, STATISTICAL; NEOPLASMS; NEUTROPHILS; NONLINEAR DYNAMICS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862262408     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9603-3     Document Type: Article

References (46)

1. Zamboni WC, D'Argenio DZ, Stewart CF, MacVittie T, Delauter BJ, Farese AM, Potter DM, Kubat NM, Tubergen D, Egorin MJ (2001) Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res 7(8):2301-2308
2. Panetta JC, Kirstein MN, Gajjar AJ, Nair G, Fouladi M, Stewart CF (2003) A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Math Biosci 186(1):29-41
3. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 63(6):1035-1048
4. Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, Igarashi T, Itoh K (1998) Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64(5):511-521. doi:10.1016/S0009-9236(98)90134-5
5. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20(24):4713-4721. doi:10.1200/JCO.2002.02.140
6. Léger F, Loos WJ, Bugat R, Mathijssen RHJ, Goffinet M, Verweij J, Sparreboom A, Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76(6):567-578
7. Troconiz IF, Garrido MJ, Segura C, Cendros JM, Principe P, Peraire C, Obach R (2006) Phase i dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 57(6):727-735
8. Van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RAA, Punt CJA, Armand JP, Raymond E, Huitema ADR, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JHM (2005) Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Investig New Drugs 23(3):225-234
9. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD (2006) A semimechanistic-physiologic population pharmacokinetic/pharmaco-dynamicmodel for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57(4):412-426
10. Hing J, Perez-Ruixo JJ, Stuyckens K, Soto-Matos A, Lopez-Lazaro L, Zannikos P (2008) Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (et-743, yondelis) induced neutropenia. Clin Pharmacol Ther 83(1):130-143. doi:10.1038/sj.clpt.6100259
11. Brain EGC, Rezai K, Lokiec F, Gutierrez M, Urien S (2008) Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n=1 randomized study. Br J Clin Pharmacol 65(4):607-610
12. Kathman SJ, Williams DH, Hodge JP, Dar M (2007) A bayesian population pk-pd model of ispinesib-induced myelosuppression. Clin Pharmacol Ther 81(1):88-94
13. Kathman SJ, Williams DH, Hodge JP, Dar M (2009) A bayesian population pk-pd model for ispinesib/docetaxel combinationinduced myelosuppression. Cancer Chemother Pharmacol 63 (3):469-476
14. Soto E, Staab A, Tillmann C, Trommeshauser D, Fritsch H, Munzert G, Troconiz IF (2010) Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemother Pharmacol 66(4):785-95
15. Ng CM, Patnaik A, Beeram M, Lin CC, Takimoto CH (2010) Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. Cancer Chemother Pharmacol. doi:10.1007/s00280-010-1393-y
16. Hansson EK, Wallin JE, Lindman H, Sandström M, Karlsson MO, Friberg LE (2010) Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol 65(5):839-848
17. Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JHM, Huitema ADR (2008) Pk/pd model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 83(6):829-839. doi:10.1038/sj.clpt.6100344
18. Zandvliet AS, Schellens JHM, Dittrich C, Wanders J, Beijnen JH, Huitema ADR (2008) Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol 66(4):485-497. doi:10.1111/j.1365-2125.2008. 03230.x
19. Segura C, Bandres E, Troconiz IF, Garcia-Foncillas J, Sayar O, Dios-Vieitez C, Renedo MJ, Garrido MJ (2004) Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. Pharm Res 21 (4):567-573
20. Ozawa K, Minami H, Sato H (2007) Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxelinduced neutropenia in japanese cancer patients. Cancer Sci 98 (12):1985-1992
21. Sandstrom M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO (2005) Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicindocetaxel regimen in breast cancer patients. J Clin Oncol 23 (3):413-421
22. Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO (2006) Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicincyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 58(2):143-156
23. Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Féty R, De Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers AHGJ, Twelves C, Beijnen JH, Schellens JHM (2007) Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the eortc-pamm-nddg. Clin Pharmacokinet 46(12):1051-1068
24. Joerger M, Huitema ADR, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Féty R, Van Der Vijgh WJF, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AHGJ, Twelves C, Beijnen JH, Schellens JHM (2007) Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the european organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13(21):6410-6418. doi:10.1158/1078-0432.CCR-07-0064
25. Zandvliet AS, Schellens JHM, Copalu W, Beijnen JH, Huitema ADR (2009) Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. J Pharmacokinet Pharmacodyn 36(1):39-62
26. Ramon-Lopez A, Nalda-Molina R, Valenzuela B, Perez-Ruixo JJ (2009) Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients. Pharm Res 26(8):1952-1962
27. Latz JE, Schneck KL, Nakagawa K, Miller MA, Takimoto CH (2009) Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between japanese and western patients. Clin Cancer Res 15(1):346-354
28. Puisset F, Alexandre J, Treluyer JM, Raoul V, Roche H, Goldwasser F, Chatelut E (2007) Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 97(3):290-296
29. Joerger M, Huitema ADR, Huizing MT, Willemse PHB, De Graeff A, Rosing H, Schellens JHM, Beijnen JH, Vermorken JB (2007) Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 64(5):622-633
30. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 12(18):5481-5490
31. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase ii studies in patients with cancer. J Clin Oncol 16(1):187-196
32. Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (taxotere): model building and validation. J Pharmacokinet Biopharm 24(2):153-172
33. Ganong W (2010) Review of medical physiology, 23rd edition. The McGraw Hill companies, U.S ISBN: 0-07-144040-2
34. th edition. The McGraw Hill companies. U.S Book ISBN: 978-0-07-162144-1
35. Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ (2000) Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (dmdc). Eur J Clin Pharmacol 56(8):567-574
36. Karlsson MO, Port RE, Ratain MJ, Sheiner LB (1995) A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 57(3):325-334
37. Beal S, Sheiner L, Boeckmann A, Bauer R (1989-2009) Nonmem user's guides. Elliot City, MD, USA
38. Lindbom L, Pihlgren P, Jonsson EN (2005) Psn-toolkit - a collection of computer intensive statistical methods for nonlinear mixed effect modeling using nonmem. Comput Methods Programs Biomed 79(3):241-257
39. Jonsson EN, Karlsson MO (1999) Xpose-an s-plus based population pharmacokinetic/pharmacodynamic model building aid for nonmem. Comput Methods Programs Biomed 58(1):51-64
40. Leger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E (2004) Mechanism-based models for topotecan-induced neutropenia. Clin Pharmacol Ther 76(6):567-578
41. Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82(1):17-20. doi:10.1038/sj.clpt.6100241
42. van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roche HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH (2005) Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 23(3):225-234
43. Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza L, Dexter TM (1989) The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86(23):9499-9503
44. Schmitz S, Franke H, Brusis J, Wichmann HE (1993) Quantification of the cell kinetic effects of g-csf using a model of human granulopoiesis. Exp Hematol 21(6):755-760
45. Price TH, Chatta GS, Dale DC (1996) Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 88(1):335-340
46. Dancey JT, Deubelbeiss KA, Harker LA, Finch CA (1976) Neutrophil kinetics in man. J Clin Invest 58(3):705-715